Items where authors include "Lester, J."

Article

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Fennell, D.A. orcid.org/0000-0001-7373-1312, Porter, C., Lester, J. et al. (8 more authors) (2022) Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): a multicentre, randomised, controlled, phase 2 trial. eClinicalMedicine, 52. 101595. ISSN 2589-5370

Fennell, D.A. orcid.org/0000-0001-7373-1312, Porter, C., Lester, J. et al. (14 more authors) (2022) Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine, 48. 101432. ISSN 2589-5370

Wu, Y. orcid.org/0000-0003-4080-3935, Biswas, D. orcid.org/0000-0001-9141-5188, Usaite, I. et al. (302 more authors) (2022) A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer. Nature Cancer, 3. pp. 696-709. ISSN 2662-1347

Fennell, D.A., Kirkpatrick, E., Cozens, K. et al. (13 more authors) (2018) CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. TRIALS, 19. 233. ISSN 1745-6215

Arce Vargas, F., Furness, A.J.S., Litchfield, K. et al. (249 more authors) (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell, 33 (4). 649-663.e4. ISSN 1535-6108

Zeng, C., Guo, X., Long, J. et al. (234 more authors) (2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 18 (1). 64. ISSN 1465-542X

Hollestelle, A., van der Baan, F.H., Berchuck, A. et al. (355 more authors) (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 141 (2). pp. 386-401. ISSN 0090-8258

Dunning, A.M., Michailidou, K., Kuchenbaecker, K.B. et al. (245 more authors) (2016) Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics. ISSN 1061-4036

Couch, F.J., Wang, X., McGuffog, L. et al. (267 more authors) (2013) Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genetics, 9 (3). e1003212. ISSN 1553-7390

Lester, J. and Coleman, R. orcid.org/0000-0002-4275-1043 (2005) Bone loss and the aromatase inhibitors. British Journal of Cancer, 93. S16-S22. ISSN 0007-0920

Proceedings Paper

Simoes, R., Patel, E., Groom, N. et al. (8 more authors) (2018) PO-1068: ADSCAN: Feasibility of implementing adequate technology for a 'pick the winner' trial in lung cancer. In: Radiotherapy and Oncology. ESTRO 37, 20-24 Apr 2018, Barcelona, Spain. , S599-S600.

Lawless, C., Boyd, K., Faivre-Finn, C. et al. (9 more authors) (2018) ADSCaN: a randomised phase ii study of accelerated, dose escalated, sequential chemo-radiotherapy in non-small cell lung cancer (NSCLC). In: Lung Cancer. The 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin . Elsevier , S88-S89.

Hanna, G., Griffiths, G., Kirkpatrick, E.V. et al. (11 more authors) (2018) CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. In: Lung Cancer. 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin. Elsevier , S84-S84.